A new study reports that cryoablation could help manage oligoprogressive disease—situations where cancer progression occurs only in a few lesions while broader disease remains controlled. The research frames a potential alternative to abandoning systemic therapy when limited resistant sites flare. The clinical decision point remains challenging for oncologists: whether to continue systemic treatment and eradicate isolated lesions or switch therapies entirely. By targeting the few “rebel” lesions, cryoablation could preserve the benefit of an otherwise effective regimen. For the sector, this is relevant because it speaks to how treatment strategies are evolving beyond one-size-fits-all schedules toward lesion-level interventions guided by imaging and disease kinetics. As data expand, the main questions will include patient selection, lesion size/location constraints, procedural safety, and durability of disease control compared with standard systemic changes.